Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

Dawn L. Hershman, MD
Published: Tuesday, Jun 23, 2015



Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) comapred to continuous ADT in prostate cancer.

The study looked at multiple late effects across both groups, including ischemic and thrombotic events, bone fractures, diabetes, obesity, depression, dementia, and sexual dysfunction.

There was a statistically significant higher rate of ischemic and thrombotic late effects among patients who had received intermittent ADT compared to continuous ADT. Other types of late effects were for the most part similar across the two groups, says Hershman.

These findings suggest more research is needed on the late effects of intermittent ADM before it should be commonly utilized, says Hershman.
 


Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) comapred to continuous ADT in prostate cancer.

The study looked at multiple late effects across both groups, including ischemic and thrombotic events, bone fractures, diabetes, obesity, depression, dementia, and sexual dysfunction.

There was a statistically significant higher rate of ischemic and thrombotic late effects among patients who had received intermittent ADT compared to continuous ADT. Other types of late effects were for the most part similar across the two groups, says Hershman.

These findings suggest more research is needed on the late effects of intermittent ADM before it should be commonly utilized, says Hershman.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x